Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Avidity Biosciences, Inc. (RNA) EBITDA (2019 - 2025)

Avidity Biosciences' EBITDA history spans 7 years, with the latest figure at -$236.3 million for Q4 2025.

  • For Q4 2025, EBITDA fell 121.97% year-over-year to -$236.3 million; the TTM value through Dec 2025 reached -$685.0 million, down 114.37%, while the annual FY2025 figure was -$685.0 million, 114.37% down from the prior year.
  • EBITDA reached -$236.3 million in Q4 2025 per RNA's latest filing, down from -$174.5 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$23.8 million in Q1 2021 to a low of -$236.3 million in Q4 2025.
  • Average EBITDA over 5 years is -$75.4 million, with a median of -$51.4 million recorded in 2023.
  • Peak YoY movement for EBITDA: tumbled 291.82% in 2021, then decreased 3.24% in 2023.
  • A 5-year view of EBITDA shows it stood at -$38.7 million in 2021, then fell by 28.36% to -$49.7 million in 2022, then decreased by 17.57% to -$58.4 million in 2023, then tumbled by 82.16% to -$106.5 million in 2024, then crashed by 121.97% to -$236.3 million in 2025.
  • Per Business Quant, the three most recent readings for RNA's EBITDA are -$236.3 million (Q4 2025), -$174.5 million (Q3 2025), and -$158.3 million (Q2 2025).